Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics (ATLANTIS)
Status
Conditions
Treatments
Details and patient eligibility
About
The ATLANTIS-study was designed to determine the safety of a full paracentesis in patients with malignant ascites due to ovarian cancer. The underlying hypothesis states, that full paracentesis does not impair safety, compared to fractioned paracentesis with clamping of the drain. Half of the patients will receive a full paracentesis, while the other half will receive fractioned paracentesis with clamping of the drain after 3 liters of ascites was evacuated. All patients receive extensive monitoring of hemodynamics and kidney function.
Full description
Background: Malignant ascites is common in ovarian cancer and often causes symptoms such as abdominal pressure and shortness of breath, resulting in an decreased quality of life for the patient. Paracentesis is a safe and easy method for symptom relief. But no guidelines exist on the management of ascites drainage in ovarian cancer. In many cases a partial paracentesis is performed, due to fear of hemodynamic instability or kidney failure, with partial drainage of the intraperitoneal fluid on the first day and subsequent drainage on the next day. As there is no study that reported a deteriorated health due to full paracentesis in ovarian cancer, the decision whether a partial or total paracentesis is performed depends entirely on the department or the physician.
Since a total paracentesis can be performed as an out-patient treatment, this approach is often preferred by the patient. Full paracentesis is also more efficient and cost-effective.
The objective of the ATLANTIS-study is to prove the safety of total paracentesis regarding hemodynamic changes and kidney failure.
Methods: ATLANTIS is a randomized, prospective, clinical study that aims to include 60 patients. Patients with histologically confirmed epithelial ovarian, fallopian tube and peritoneal cancer are randomized into two arms: Partial (3 Liter) and total paracentesis. Before, during and for two hours after the paracentesis, an advanced hemodynamic monitoring is performed to ensure the patients' safety. The monitoring includes mean arterial pressure and stroke volume. After the initial phase of extensive monitoring (2 hours), the blood pressure is measured for a period of 24 hours to evaluate not only short term, but also long-term hemodynamic changes. Before and 24 hours after the paracentesis, blood samples are analyzed to detect a potential acute kidney failure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Histologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer
- Symptomatic (e.g. abdominal pressure, pain, shortness of breath) malignant ascites with clinical indication for paracentesis and sonographic estimate of >3 liters
- Patient information and written informed consent
Exclusion criteria
- Age <18 years
- Missing written informed consent
- Lack of sufficient knowledge of german or english language
- No willingness to consent to the storage or distribution of anonymised disease-specific data inside the clinical trial
- Placement inside a state facility due to judicial order
- Employee status at Charite-University Medicine of Berlin
- Chronic kidney insufficiency defined as serum creatinin levels >1,2 g/dl at time point of admission
- Active neurologic/psychiatric disorder at time point of admission
- Cardiac insufficiency defined as >NYHA I at time point of admission
- Manifest ileus at time point of admission
- Manifest chronic arterial hypo- or hypertension, defined as chronic baseline systolic pressure of <90 or >140 mmHg and diastolic pressure of <70 and >90 mmHg
- Active infection
- Blood clotting disorder (congenital or acquired)
- Thrombocytopenia (platelets <80 000/nl)
- Active participation in another clinical intervention trial at time point of admission
- Chronic atrial fibrillation on time point of admission
- Status post cardiac pacer implantation
- Liver cirrhosis
- Liver metastases
Trial design
Primary purpose
Allocation
Interventional model
Masking
61 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal